Cae3313- A Prospective Phase II Trial Of Novottf-100A With Bevacizumab (Avastin) In Patients With Recurrent Glioblastoma
Posted Date: May 15, 2019
- Investigator: Rekha Chaudhary
- Specialties: Breast Cancer, Cancer, Oncology
- Type of Study: Drug
The purpose of this study is to determine the efficacy of the combination of Bevacizumab and NovoTTF-100A in Bevacizumab na?ve (meaning you have never received bevacizumab before) patients with recurrent GBM as measured by 6-month progression free survival.
Criteria:
To Be Eligible For This Study, Patients Must Have Been Diagnosed With A Brain Tumor Called Glioblastoma, Age Over 22, No Known Severe And Uncontrolled Infection Or Illness, Nonpregnant And Nonbreastfeeding
Keywords:
Cancer, Glioma, Brain Tumor, Cae3313, Brain
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com